These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3680569)

  • 21. Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.
    Patnaik RN; Lesko LJ; Chen ML; Williams RL
    Clin Pharmacokinet; 1997 Jul; 33(1):1-6. PubMed ID: 9250419
    [No Abstract]   [Full Text] [Related]  

  • 22. [Assessment of bioequivalence].
    Aoyagi N
    Eisei Shikenjo Hokoku; 1996; (114):141-2. PubMed ID: 9037886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug.
    Sperry DC; Thomas SJ; Lobo E
    Mol Pharm; 2010 Oct; 7(5):1450-7. PubMed ID: 20704266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chiral bioequivalence: effect of absorption rate on racemic etodolac.
    Boni JR; Korth-Bradley JM; Richards LS; Chiang ST; Hicks DR; Benet LZ
    Clin Pharmacokinet; 2000 Dec; 39(6):459-69. PubMed ID: 11192477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products.
    Mitra A; Petek B; Bajc A; Velagapudi R; Legen I
    Eur J Pharm Biopharm; 2019 Jan; 134():117-125. PubMed ID: 30472143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The assessment of individual and population bioequivalence.
    Chinchilli VM
    J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolites and bioequivalence: past and present.
    Jackson AJ; Robbie G; Marroum P
    Clin Pharmacokinet; 2004; 43(10):655-72. PubMed ID: 15244496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence studies: single vs multiple dose.
    Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):261-6. PubMed ID: 2737794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The basis for individual bioequivalence. FDA Population and Individual Bioequivalence Working Group.
    Williams RL; Patnaik RN; Chen ML
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):13-7. PubMed ID: 11032083
    [No Abstract]   [Full Text] [Related]  

  • 31. The duration of measuring partial AUCs for the assessment of bioequivalence.
    Endrenyi L; Csizmadia F; Tothfalusi L; Balch AH; Chen ML
    Pharm Res; 1998 Mar; 15(3):399-404. PubMed ID: 9563068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies.
    Blume HH; Midha KK
    J Pharm Sci; 1993 Nov; 82(11):1186-9. PubMed ID: 7904641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence.
    Shah VP; Flynn GL; Yacobi A; Maibach HI; Bon C; Fleischer NM; Franz TJ; Kaplan SA; Kawamoto J; Lesko LJ; Marty JP; Pershing LK; Schaefer H; Sequeira JA; Shrivastava SP; Wilkin J; Williams RL
    Pharm Res; 1998 Feb; 15(2):167-71. PubMed ID: 9523299
    [No Abstract]   [Full Text] [Related]  

  • 34. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and psychopharmacology: application to the geropsychiatric patient.
    Keltner NL; Folks DG
    Perspect Psychiatr Care; 1993; 29(1):34-6. PubMed ID: 8451165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence assessment of generic drugs: an American point of view.
    Patnaik R; Lesko LJ; Chan K; Williams RL
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):159-64. PubMed ID: 8839690
    [No Abstract]   [Full Text] [Related]  

  • 37. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats.
    Chiou WL; Barve A
    Pharm Res; 1998 Nov; 15(11):1792-5. PubMed ID: 9834005
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.